BioCentury
ARTICLE | Company News

Management tracks: Intellia, Spectrum

December 20, 2017 12:18 AM UTC

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) said CEO Nessan Bermingham will resign, effective Jan. 1. EVP of R&D John Leonard will succeed Bermingham.

Hematology and cancer company Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) said CEO Rajesh Shrotriya has been terminated. President and COO Joseph Turgeon succeeds Shrotriya as president and CEO. EVP, Chief Commercial Officer and Head of Business Development Thomas Riga succeeds Turgeon as COO...